4basebio is enabling next generation cell and gene therapies and vaccines with it's technologies and solutions. We are able to design, manufacture and supply application-specific synthetic DNA or mRNA as well as targeted non-viral vectors for the delivery of nucleic acid payloads. Our novel synthetic DNA technology offers unique customisation potential, rapid turn-around times, and improved safety profiles, addressing the current limitations of plasmids and other DNA technologies. We currently offer four DNA construct types, each ideally suited for use in viral and non-viral vector applications, genome editing, vaccines and therapeutics, and DNA vaccine applications, respectively. Our proprietary non-viral delivery system, Hermes™, is a nanoparticle vector that can be customised to target cells or tissues of interest for a range of applications. This combines the safety and efficiency of lipid-based nanoparticles (LNPs) with the specificity of a targeting system, addressing the shortcoming associated with both viral vectors and non-targeted LNPs.
| Website | https://www.4basebio.com/ |
| Revenue | $8.2 million |
| Employees | 141 (99 on RocketReach) |
| Industry | Biotechnology |
| Keywords | Gene Therapy, Cell Therapy, Synthetic Dna, Mrna Technology, Targeted Therapies, Vaccine Development, Genetic Engineering, Next Generation Vaccines, Biotechnology, Therapeutics, Precision Medicine, Drug Development, Molecular Biology, Biopharma, Pharmaceutical, Life Sciences |
| Competitors | Thermo Fisher Scientific, Agilent Technologies, Illumina, QIAGEN, 10x Genomics, Fulgent Genetics, PacBio, 5AM Ventures, Zymergen, Inc., BD Biosciences +41 more (view full list) |
Looking for a particular 4basebio employee's phone or email?
The 4basebio annual revenue was $8.2 million in 2026.
Amy Walker is the CEO of 4basebio.
99 people are employed at 4basebio.